Huo Mengmeng, Guo Wanying, Ding Liqiong
Department of Pharmaceutics, School of Pharmacy, Hubei University of Science and Technology, Xianning, People's Republic of China.
J Inflamm Res. 2024 Sep 11;17:6307-6316. doi: 10.2147/JIR.S467796. eCollection 2024.
NLRP3, ASC, and procaspase-1 form the multiprotein complex known as the NLRP3 inflammasome. Following the priming of NLRP3 by TLR4 ligand, the activation of the NLRP3 inflammasome causes caspase-1 maturation, which results in the release of IL-1β. Calcium channel antagonists are commonly employed as antihypertensive medications and have anti-inflammatory properties through the inhibition of cytokine release, specifically IL-1β. The impact of calcium channel antagonists on NLRP3 inflammasomes, however, has not been well studied. This study aimed to investigate the effect of the calcium channel blocker benidipine hydrochloride on LPS-induced NLRP3 inflammasome activation in THP-1 macrophages and its possible mechanism.
Firstly, the cytotoxicity of benidipine hydrochloride was determined by MTT. The effect of benidipine hydrochloride on LPS-induced IL-1β release was determined by ELISA. Then, the effect of benidipine hydrochloride on the expression of IL-1β, NLRP3, ASC, and Caspase-1 induced by LPS was determined by QPCR, and the expression of IL-1β, GSDMD, Caspase-1, and their active forms was determined by Western blot, and the activation of NF-κB was determined by Western blot and immunofluorescence. Finally, the production of ROS was determined by flow cytometry and fluorescence microscopy.
Benidipine hydrochloride was found to drastically lower the expression of NLRP3, ASC, and caspase 1, which in turn decreased the amount of IL-1β secreted by THP-1 macrophages. Benidipine hydrochloride dramatically reduced the phosphorylation level of NF-κB p65 and its nuclear translocation in THP-1 macrophages. Furthermore, benidipine hydrochloride significantly decreased the generation of ROS.
Based on these results, we deduced that benidipine hydrochloride prevents ROS formation in THP-1 macrophages and LPS-induced NF-κB signaling, which in turn prevents the activation of NLRP3 inflammasomes and the release of IL-1β.
NLRP3、ASC和半胱天冬酶原-1形成了被称为NLRP3炎性小体的多蛋白复合物。在Toll样受体4(TLR4)配体引发NLRP3之后,NLRP3炎性小体的激活会导致半胱天冬酶-1成熟,进而导致白细胞介素-1β(IL-1β)的释放。钙通道拮抗剂通常用作抗高血压药物,并通过抑制细胞因子释放,特别是IL-1β,而具有抗炎特性。然而,钙通道拮抗剂对NLRP3炎性小体的影响尚未得到充分研究。本研究旨在探讨钙通道阻滞剂盐酸贝尼地平对脂多糖(LPS)诱导的THP-1巨噬细胞中NLRP3炎性小体激活的影响及其可能机制。
首先,通过MTT法测定盐酸贝尼地平的细胞毒性。通过酶联免疫吸附测定(ELISA)法测定盐酸贝尼地平对LPS诱导的IL-1β释放的影响。然后,通过实时定量聚合酶链反应(QPCR)法测定盐酸贝尼地平对LPS诱导的IL-1β、NLRP3、ASC和半胱天冬酶-1表达的影响,通过蛋白质免疫印迹法测定IL-1β、Gasdermin D(GSDMD)、半胱天冬酶-1及其活性形式的表达,并通过蛋白质免疫印迹法和免疫荧光法测定核因子κB(NF-κB)的激活情况。最后,通过流式细胞术和荧光显微镜测定活性氧(ROS)的产生。
发现盐酸贝尼地平可显著降低NLRP3、ASC和半胱天冬酶1的表达,进而减少THP-1巨噬细胞分泌的IL-1β量。盐酸贝尼地平显著降低了THP-1巨噬细胞中NF-κB p65的磷酸化水平及其核转位。此外,盐酸贝尼地平显著降低了ROS的产生。
基于这些结果,我们推断盐酸贝尼地平可防止THP-1巨噬细胞中ROS的形成以及LPS诱导的NF-κB信号传导,进而防止NLRP3炎性小体的激活和IL-1β的释放。